shutterstock_1953872293_marlon_trottmann

Marlon Trottmann / Shutterstock.com

13 December 2022AmericasStaff Writer

Amgen seals $28m deal for biotech

Two rivals withdrew from acquisition process | Agreement provides access to blockbuster medicines | Janssen Global Services | Sanofi.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

More on this story

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

More on this story

FTC sues to bar Amgen from major IP $28bn acquisition

18 May 2023 The $27.8 billion acquisition would allegedly enable the pharma giant to stifle competition for thyroid eye disease and chronic refractory gout treatments | There is currently no market competition for the treatments.

Amgen continues M&A flurry with $3.7bn deal

8 August 2022 Pharma company to acquire biopharma focused on autoimmune, inflammatory and cancer therapeutics / Deal includes acquisition of Tavneos / Spate of acquisitions follows increased competition.

More features

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims

ResMed voids sleep apnoea tech patent at PTAB